COMMON STOCK PURCHASE WARRANT NKGEN BIOTECH, INC.Common Stock Purchase Warrant • April 5th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances)
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the unsecured promissory note in the principal amount of $330,000.00 to the Holder (as defined below) of even date) (the “Note”), AJB CAPITAL INVESTMENTS LLC, a Delaware limited liability company (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from NKGEN BIOTECH, INC., a Delaware corporation (the “Company”), 330,000 shares of Common Stock (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated April 1, 2024, by and among the Com
SECURITIES PURCHASE AGREEMENTRegistration Rights Agreement • April 5th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 1, 2024, by and between NKGEN BIOTECH, INC., a Delaware corporation, with headquarters located at 3001 Daimler Street, Santa Ana, CA, 92705 (the “Company”), and Sandia Investment Management LP on behalf of Diametric True Alpha Market Neutral Master Fund LP and Diametric True Alpha Enhanced Market Neutral Master Fund, with its address at 201 Washington Street, Boston, MA 02108 (the “Buyer”).
